Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.
Zacks
More News
ResMed Analyst Backs Portfolio Reset
ResMed is selling MatrixCare for $490 million to sharpen its sleep health focus as analysts weigh near-term EPS dilution against long-term growth.read more...
Benzinga
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks
ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?
ResMed (RMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks
Here's Why ResMed (RMD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
ResMed (RMD) Upgraded to Buy: Here's Why
ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Wall Street Analysts Think ResMed (RMD) Could Surge 28.21%: Read This Before Placing a Bet
The mean of analysts' price targets for ResMed (RMD) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Zacks
Are Options Traders Betting on a Big Move in ResMed Stock?
Investors need to pay close attention to RMD stock based on the movements in the options market lately.